When Acadia was negotiating with Neuren they were able to look under the hood at NNZ2591 and obviously like what they saw and that why they were very keen to get their hands on NNZ2591 for retts syndrome and Fragile X only .The negotiations went on for a year and they had some very serious competition I believe .
Ann: Q2 2023 quarterly activity and cash flow report, page-14
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.60 |
Change
0.740(3.73%) |
Mkt cap ! $2.583B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.61 | $19.94 | $3.512M | 173.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 178 | $20.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.61 | 513 | 3 |
View Market Depth
| Last trade - 12.57pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |